In two randomized, placebo-controlled trials conducted in HNC patients undergoing postoperative chemoradiotherapy and in patients receiving definitive chemoradiotherapy for locally advanced HNC, intravenous palifermin, a truncated human recombinant keratinocyte growth factor (KGF), administered weekly for 8 weeks decreased severe OM (4,23). Here, FGF7 is linked to ocular melanoma.